Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136091 · ClinicalTrials.gov registry record
Protocol CAUSE-03 / CHEETAH
A clinical trial of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 310
- Enrollment target
- 8
- Study locations
NCT06136091 is a study of Asthma that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 310 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT06136091, a study of Asthma, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 310 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot have used asthma medications in the year prior to enrollment and cannot demonstrate bronchodilator reversibility at baseline. Phenotypic characteristics will be established at baseline, and the participants will be seen at scheduled visits over 12 months. Each participant will be asked to monitor and self-report cold symptoms and will be asked to complete up to three cold visits
Conditions Studied
Study Locations (8)
Massachusetts
- Boston University School of Medicine: Pulmonary Center - Boston
- Boston Children's Hospital: Department of Immunology - Boston
New York
- Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute - New York
- Columbia University Medical Center: Division of Pediatric Pulmonology - New York
Colorado
- Children's Hospital Colorado: Allergy Program - Aurora
District of Columbia
- Children's National Medical Center: Children's Research Institute - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology - Chicago
Ohio
- Cincinnati Children's Hospital Medical Center: Asthma Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-04-23 |
| Est. Completion | 2027-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06136091
The ClinicalTrials.gov registry entry for NCT06136091 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT06136091 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT06136091 about?
NCT06136091 is a clinical study titled "Protocol CAUSE-03 / CHEETAH". This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot h...
What is the current status of trial NCT06136091?
This trial is currently recruiting. The enrollment target is 310 participants. The study started on 2024-04-23. Estimated completion is 2027-05-01.
What conditions does trial NCT06136091 study?
This clinical trial studies the following conditions: Asthma.
Who is sponsoring clinical trial NCT06136091?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136091 being conducted?
This trial has 8 study locations across Colorado, District of Columbia, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.